A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

作者：Jeffrey V. Lazarus, Paul Brennan, Henry E. Mark, William Alazawi, Alina M. Allen, Christopher D. Byrne, Laurent Castéra, Cyrielle Caussy, Kenneth Cusi, Martin M. Grajower, Christopher J. Kopka, Jo Massoels, Michael Roden, C Wendy Spearman, Frank Tacke, Vincent Wai‐Sun Wong, Mazen Noureddin · 发表于：The Lancet Regional Health - Europe · 年份：2025 · DOI：10.1016/j.lanepe.2025.101320 · 被引用次数：19 · 研究领域：Liver Disease Diagnosis and Treatment、Diet, Metabolism, and Disease、Pancreatitis Pathology and Treatment

Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.